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Chlorofluorocarbon (CFC)-containing inhalers for use in the treatment of asthma are to be phased out under the
terms of the Montreal Protocol (1). In this multi-centre, randomized, double-blind study, the therapeutic
equivalence of two formulations of beclomethasone dipropionate (BDP) containing CFC or non-CFC (HFA134a)
propellant, both delivered via the EasibreatheTM (Norton Healthcare Ltd, London, U.K.) inhaler, was determined
in 229 asthmatic children. Each child received 100 mg doses of BDP (containing either CFC or HFA propellant)
twice daily for 12 weeks.
Both CFC and HFA formulations produced statistically and clinically significant improvements in patient’s lung
function and symptom scores when administered via the EasibreatheTM inhaler. The improvements in mean
morning peak expiratory flow (PEF) were 41 l min71 and 34 l min71 for the BDP-HFA and BDP-CFC products
respectively (P50001) and for mean evening PEF the improvements were 38 l min71 and 38 lmin71, respectively
(P50001). Similar findings were demonstrated for the other ecacy parameters. The two formulations were
statistically equivalent with respect to ecacy. For mean morning PEF the estimated treatment dierence (BDP-
CFC/BDP-HFA ratio) was 1026% (95% Cl 991, 1062). Similar equivalence was shown for the other ecacy
parameters. Both products were well tolerated, with no dierence in the adverse event profiles, eects on 24 h
urinary cortisol or Candida colonisation.
This study demonstrates that the new formulation of BDP with HFA-134a propellant is equivalent to and
directly substitutable for BDP with the older CFC propellant in a dose for dose manner. This should enable a
seamless transition from one product to the other when CFC containing products are eventually phased out. In
addition this study has also shown that the EasibreatheTM inhaler is an eective delivery system for use with inhaled
products for the treatment of asthma in children.
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Beclomethasone dipropionate (BDP) is a corticosteroid
indicated for the prophylactic management of asthma.
Although the action of BDP is anti-inflammatory (2) and
the exact mechanism of corticosteroid action within the
lung is not fully understood, treatment with BDP reducesReceived 22 January 1999 and accepted in revised form 23 July
1999.
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0954-6111/00/010057+07 $35?00/0bronchial mucosal inflammation with consequent reduction
of bronchial oedema and mucus secretion.
Treatment with BDP for the prophylactic management
of asthma is invariably by inhalation. This is commonly via
a pressurized metered-dose inhaler (pMDI). Currently,
most pMDIs utilize a conventional chlorofluorocarbon
(CFC) propellant to form an aerosol of BDP for inhalation.
Under the terms of the Montreal Protocol (1), use of such
CFC propellants is to be phased out due to their ozone
depleting potential.
A CFC-free formulation of BDP has been developed
(Norton Healthcare Ltd.) which utilizes 1,1,1,2-tetrafluor-
oethane, a hydrofluorocarbon propellant (commonly
known as HFA-134a) and which is predicted to have# 2000 HARCOURT PUBLISHERS LTD
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toxicology of this HFA molecule have been studied
extensively by the International Pharmaceutical Aerosol
Consortium for Toxicology Testing (IPACT-1). Further
testing by pharmaceutical companies has shown that this
propellant is free from any serious toxicity. Single- and
multi-dose studies of HFA-134a in healthy humans have
shown that it is well tolerated at dose levels well above
those required for use in inhalation devices (3–5).
Other BDP products containing HFA-134a have recently
been evaluated (6–8). These studies have shown that in
combination with HFA-134a, beclomethasone dipropio-
nate is as safe and as eective as the currently available
CFC-containing products (6). Although a dose switch from
CFC to CFC-free products is a desirable course of action, it
has been suggested that due to the fine particle character-
istics of the new formulations, it may be possible to reduce
the eective dose by up to 50% (7,8). Whilst dose reduction
has obvious clinical benefits, any such reductions must be
closely supervised and should be carefully balanced against
potential confusion that may be caused to the patient. The
BDP formulation in this current study has been developed
to allow a seamless dose for dose transition from CFC to
CFC-free inhaler.
A novel breath-operated inhaler device (EasibreatheTM)
has been specifically designed to overcome the co-ordina-
tion problems patients experience when using standard
pMDIs.
The aim of this study was to assess therapeutic
equivalence and comparable safety of BDP-HFA and
BDP-CFC both via EasibreatheTM inhaler when adminis-
tered to asthmatic children.
Patients and methods
PATIENTS
Asthmatic children aged 7–12 years (inclusive) were eligible
for the study. Patients were recruited from 44 General
Practice and Hospital sites in the U.K., South Africa, the
Czech Republic, Yugoslavia and Hungary. All patients and
their parent/guardian gave written informed consent to the
child’s participation. At baseline all patients were required
to demonstrate a forced expiratory volume in 1 sec (FEV1)
of at least 60% of that predicted for their height and
gender, and a reversibility of at least 10% in FEV1
following inhalation of a standard 200 mg dose of
salbutamol from a pMDI. Patients with a documented
reversibility in FEV1 of 10% recorded in the previous 12
months were also allowed to participate. Each patient was
currently receiving an inhaled bronchodilator b2-agonist
and may also have been receiving sodium cromoglycate or
nedocromil sodium (provided the dose remained constant
throughout the study). Patients currently receiving inhaled
corticosteroids or oral corticosteroids, or patients with
unstable asthma, were excluded from the study. Patients
with any significant medical or psychological conditions
were also excluded.Study design
This investigation was a randomized, double-blind, parallel
group study. The patents were randomized in ascending
numerical order at each site according to a predetermined
random code generated by the Statwood Partnership.
Eligible patients entered a 2 week placebo run-in period,
during which they were instructed to take one pu twice
daily from a CFC placebo EasibreatheTM inhaler. Patients
used a mini-Wright Peak Flow MeterTM (Clement Clarke
International Ltd., U.K.), to record twice daily PEF
readings throughout the study. In addition patients also
recorded daily use of relief bronchodilator and daytime and
night-time asthma symptoms. At the end of the run-in
period, each patient was required to have used relief
bronchodilator (two pus or more) on at least 3 days out of
the last seven of the run-in period. Eligible patients were
then randomized to receive either BDP-CFC or BDP-HFA
at a dose of 100 mg twice daily via the EasibreatheTM
inhaler for the next 12 weeks. Data recorded on diary cards
were the same as for the run-in period. Each patient re-
attended the clinic at 1, 4, 8 and 12 weeks after
randomization. At each visit assessments of lung function
and emergent adverse events were made. Twenty four hour
urinary cortisol measurements were made at the start and
end of treatment in a sub-population (*20%) of the
patients. Oropharyngeal swabs for Candida albicans were
taken at the start and end of the study in all patients and
where clinically indicated on symptomatic grounds
throughout.
METHODS
Ethics committee approval was obtained as appropriate for
each participating centre.
Measurement of lung function
Prior to taking any inhaled medication, patients were
instructed to make three measurements of PEF on rising
each morning, and again each evening before going to bed,
using a mini-Wright Peak Flow MeterTM (Clement Clarke
International Ltd., Harlow, U.K.). All three recordings of
PEF on each occasion were documented by the patients on
diary cards. Spirometric assessments were made by the
investigator at each clinic visit using a calibrated Micro
spirometerTM (Micro Medical Ltd., Rochester, U.K.).
Local reference values were used.
Diary card data
Use of relief medication and symptom scores also were
recorded twice daily. Patient’s assessments of cough,
wheeze and overall symptoms were recorded using 4-point
(0–3) rating scales.
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These comprised clinical adverse events, 24 h urinary
cortisol assessments (in approximately 20% of the patients)
and presence of C. albicans on oropharyngeal swabs.
STATISTICAL METHODS
Sample size
To detect a mean dierence of 25 l min71 in morning PEF
(10% of the expected level of 250 l min71) between
treatments using a two-sided 95% confidence interval, 105
patients per treatment group were needed. This estimate
assumed a standard deviation of 50 l/min71 for each group
and 90% power. To accommodate for dropouts and
unevaluable patients, 130 patients were selected to be
randomized to each treatment group.
Efficacy analysis
Mean morning PEF was calculated from the diary cards for
weeks 11 and 12 of treatment. The data were subjected to
an analysis of covariance to allow for the eect of
treatment, using baseline measurements as covariate.
Baseline was taken to be the mean value over the last week
before randomization. A test for parallel slopes was carried
out by looking at the treatment by baseline interaction. The
student’s t-test residuals were examined for normality by
plotting the ranked values against their normal scores and
for constant variance by plotting them against the fitted
values. The ratio (expressed as percentage) of the two
treatments (HFA/CFC) was estimated and 95% confidence
intervals constructed. All other lung function parameters
were analysed in the same manner. For all outcome
variables, equivalence was declared when the 95% con-
fidence interval for the ratio of treatment means relative to
the CFC mean was completely contained within the interval
(90%, 110%).
Symptom scores were analysed using Wilcoxon rank




Age (years) Median (Range) 100
Height (m) Median (Range) 143
Weight (kg) Median (Range) 346
PEF (l min71) Mean (SD) 30
% Predicted PEF Mean (SD) 96
FEV1(l) Mean (SD 18
% Predicted FEV1 Mean (SD) 88
% FEV1
Reversibility at baseline
Mean (SD) 16with 95% confidence intervals was calculated using the
Hodges–Lehmann method. No adjustment was made for
baseline values.
Results
A total of 229 patients were recruited into the study of
whom 199 provided evaluable data. Seven patients were
withdrawn during the course of the study (four from the
BDP-HFA group and three from the BDP-CFC group). Of
these seven, two patients in each group were withdrawn for
violation of the study protocol, two in the BDP-HFA group
were withdrawn for unspecified reasons and one patient in
the BDP-CFC group was withdrawn due to an exacerba-
tion of asthma requiring hospitalisation. In addition 22
patients were excluded from the per-protocol analysis for
violations of the study protocol and a further patient was
excluded from the analysis as they had received less than 10
weeks of study medication. The ecacy analyses were
carried out on the per-protocol sample of 199 patients (103
BDP-HFA and 96 BDP-CFC). Demographic details are
given in Table 1.
The two treatment groups in the per-protocol analysis
were well matched with respect to baseline lung function.
EFFICACY
Mean morning and evening PEF in both treatment groups
increased over the study period and had reached a peak by
week 10. For the per-protocol population these increases
were statistically significant (P50001) at all post-treatment
time points (Fig. 1). The overall improvements in mean
morning PEF were 41 l min71 and 34 l min71 for the BDP-
HFA and BDP-CFC groups respectively. For mean
evening PEF the corresponding values were 38 l min71
and 32 l min71. The estimated treatment dierence for
mean morning PEF was 26% and the two treatments are
thus equivalent (Table 2). Similarly equivalent results were
obtained for mean evening PEF with the estimated
treatment dierence being 21%. Results for all of the
other lung function parameters were also equivalent. Thebaseline lung function (per-protocol population)
P-HFA BDP-CFC Total
(61%) 75 (66%) 146 (64%)
(39%) 38 (34%) 83 (36%)
(70–129) 98 (66–128) 99 (66–129)
(113–172) 141 (117–166) 142 (113–172)
(188–720) 330 (210–640) 34.8 (188–720)
8 (595) 305 (685)
4 (178) 953 (168)
2 (045) 177 (042)
0 (150) 867 (139)
7 (65) 160 (80)
FIG. 1. Mean morning and evening PEF (Per-Protocol population) for each two weeks of the treatment period. All
timepoints marked *were significantly dierent compared to baseline (P50001) .-^-: BDP-HFA (am);
-&-: BDP-CFC (am); -~-: BDP-HFA (pm); -X-: BDP CFC (pm).
TABLE 2. Analysis of lung function data (per-protocol population)
Parameter Timepoint BDP-HFA BDP-CFC Estimate (95% CI)—
HFA/CFC(%)
Mean (SD) Baseline 299 (56) 294 (62)
morning PEF Endpoint 340 (61) 328 (54)
(l min71) Endpoint1 338 330 1026 (991, 1062)
Mean (SD) Baseline 302 (57) 297 (61)
evening PEF Endpoint 340 (61) 329 (51)
(l min71) Endpoint1 338 331 1021 (9986, 1056)
Mean (SD) clinic Baseline 308 (60) 305 (69)
PEF Endpoint 335 (59) 335 (59)
(l min71) Endpoint1 337 333 1012 (973, 1051)
Mean (SD) clinic Baseline 182 (045) 177 (042)
FEV1 Endpoint 198 (045) 190 (040)
(l) Endpoint1 197 191 1035 (996, 1075)
Mean (SD) daily Baseline 208 (117) 223 (116)
variability PEF Endpoint 161 (136) 165 (109)
(%) Endpoint1 162 163 994 (786, 1169)
1Least squares mean.
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which decreased from 21–16% in the BDP-HFA group and
from 22–16% in the BDP-CFC group.
Compared to baseline there were marked, significant
decreases in the proportion of patients reporting daytime
and night-time symptoms in both of the treatment groups
and also in the proportion of patients using reliefmedication (Fig. 2). This is indicative of an overall
improvement in asthma control for both treatments.
SAFETY
There was no preponderance of any one type of adverse
event. No positive cultures for C. albicans were found at
FIG. 2. Proportion of patients (%) reporting asthma symptoms and proportion (%) of patients using relief medication.
*indicates significantly dierent to Baseline (P5005). There were no dierences between treatments for the pre- or post-
study values. &: BDP-HFA pre-study; &: BDP-CFC pre study; : BDP-HFA post-study; : BDP-CFC post study.
CFC-FREE BECLOMETHASONE DIPROPIONATE IN PAEDIATRIC ASTHMA 61baseline and at the end of study 13% of patients in the
BDP-HFA group and 9% in the BDP-CFC group had
positive cultures.
TWENTY FOUR HOUR URINARY
CORTISOL
Mean baseline 24 h urinary cortisol values was assessed in
43/229 (19%) of patients and were comparable for both
treatment groups (data from patients with only one
measurement either pre- or post-study were excluded from
this calculation). Mean baseline values were 129 nmol
24 h71 for BDP-HFA (n=24) and 150 nmol 24 h71 for
BDP-CFC (n=19). The mean post-treatment values were
125 nmol 24 h71 and 121 nmol 24 h71 respectively.
Individual patient data are presented in Fig. 3. The mean
change for the BDP-HFA group was 746 nmol 24 h71
and for the BDP-CFC group the mean change was 7285
nmol 24 h71.
Discussion
The introduction of new CFC-free propellants for asthma
inhalers has presented healthcare professionals and the
pharmaceutical industry with a number of unique chal-
lenges. Two main challenges are the determination of
therapeutic equivalence between old and new products, andevolving strategies to manage the change over with respect
to dosing levels and patient education.
In 1995 the British Association for Lung Research issued
guidelines for the determination of equivalence for inhaled
medication (9), but these did not define therapeutic
equivalence. A more recent set of guidelines published by
the Canadian Thoracic Society (10) gives detailed advice on
the design and conduct of appropriate studies, but again
falls short of a definition of therapeutic equivalence. This
current study pre-dated publication of the Canadian report,
but has included many of the recommendations that were
proposed therein.
When designing studies to demonstrate therapeutic
equivalence between asthma treatments it is important to
show comparable improvement in asthma control with
each, especially in patients who are steroid-naı¨ve, as here.
The study included a large number of patients with well
defined asthma. Patients were thoroughly trained in inhaler
use, the end points were consistent with the recommenda-
tions for establishing equivalence and the data were
analysed to present 95% confidence intervals with a tight
definition of equivalence.
This study has demonstrated that the newly formulated
BDP-HFA inhaler is therapeutically equivalent to the
existing BDP-CFC inhaler at a dose of 100 mg b.d. for
the treatment of asthma in children requiring inhaled
corticosteroids. This equivalence has been demonstrated for
all objective parameters assessed in this study (with the
exception of daily variability in PEF), with all of the 95%
FIG. 3. Individual changes in 24 h urinary cortisol levels
pre- and post-treatment (mean values are indicated by
horizontal bars).
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90–110%. The two treatments produced equivalent levels of
ecacy in terms of eect on lung function and symptom
control and had equivalent tolerability profiles. There was
no evidence of any marked eects of either treatment on
HPA function as assessed by 24 h urinary cortisol
measurements, as might be expected at this dosage level
for inhaled BDP. Mean changes in this parameter were
greater if anything in the BDP-CFC group, at the end of the
study.
For the primary ecacy endpoint, mean morning PEF,
the estimated treatment dierence was only 26%, which
represents a dierence in PEF between treatments of
85 l min71. The upper 95% Cl limit for this parameter
showed a dierence of 62%, representing a worst case
dierence between treatments of 20 l min71. Both
formulations produced similar incidences of adverse events
and these events were entirely consistent with those
expected for a population of the type enrolled into this
study.
Based on these results it appears possible to switch from
a CFC to a CFC-free BDP formulation on a dose for dose
basis. This is an important consideration which would
facilitate a seamless transition to the new CFC-free inhalers
for both clinicians and patients. Some recent studies have
suggested that it may be possible to reduce the dose of
corticosteroid by up to 50% when switching patients from
BDP-CFC to BDP-HFA (7,8). This has been based upon
the principle that, although the site of action for inhaled
corticosteroids is not yet fully known, there is a greater fine
particle deposition and penetration in the lung of BDP-
HFA than BDP-CFC and that this correlates with
enhanced ecacy. It may be argued conversely that an
increase in fine particle penetration may lead to an increase
in systemic absorption and subsequently an increase in
adverse eects; further work is required in this respect.
However, it is important to note that these dose reduction
studies have not included direct comparisons at the same
dose levels for BDP-CFC and BDP-HFA. In addition,
results of these studies have been contradicted by a further
study with the same formulation of BDP-HFA which
showed a dose for dose equivalence (6). Two recent studies
in adults (11) using the same formulation of BDP-HFA that
was used in this current study also showed a dose for dose
equivalence at both low and high doses further supporting
the findings presented in this study. It is possible that the
lack of a clinical dierence between the HFA and CFC
formulations may be a result of the relatively flat dose
response curve seen with corticosteroids, although the fact
that some studies have shown a clinical dierence contra-
dicts this.
In summary this study has shown that paediatric patients
may be switched from currently available BDP-CFC
inhalers to the new BDP-HFA inhalers at the same dose
without loss of ecacy or asthma control, and with no
changes in tolerability. In addition this study has also
confirmed the eectiveness of the EasibreatheTM inhaler in
paediatric patients irrespective of the type of propellant
used to deliver BDP.
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